Brokers Offer Predictions for OPKO Health FY2028 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Research analysts at Barrington Research upped their FY2028 earnings per share estimates for OPKO Health in a research note issued on Friday, November 8th. Barrington Research analyst M. Petusky now anticipates that the biotechnology company will earn $0.00 per share for the year, up from their prior estimate of ($0.01). Barrington Research currently has a “Outperform” rating and a $2.25 target price on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.29) per share.

Several other equities research analysts have also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Thursday, September 26th. StockNews.com raised OPKO Health to a “sell” rating in a report on Saturday, July 27th. Finally, Piper Sandler reissued an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th.

OPKO Health Trading Up 2.5 %

OPKO Health stock opened at $1.61 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.63 and a quick ratio of 1.36. OPKO Health has a one year low of $0.85 and a one year high of $1.75. The stock has a market capitalization of $1.12 billion, a PE ratio of -8.47 and a beta of 1.65. The business’s fifty day moving average is $1.51 and its 200 day moving average is $1.43.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP lifted its holdings in OPKO Health by 800.0% in the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after purchasing an additional 39,486,490 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in OPKO Health by 142.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after acquiring an additional 876,272 shares during the last quarter. Y.D. More Investments Ltd bought a new stake in OPKO Health in the 2nd quarter worth approximately $1,840,000. AWM Investment Company Inc. increased its stake in OPKO Health by 18.2% in the 1st quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company’s stock worth $1,560,000 after acquiring an additional 200,000 shares during the last quarter. Finally, PFG Investments LLC increased its stake in OPKO Health by 10.4% in the 3rd quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company’s stock worth $1,581,000 after acquiring an additional 100,125 shares during the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at OPKO Health

In other news, major shareholder Opko Health, Inc. sold 50,000 shares of OPKO Health stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $34.49, for a total transaction of $1,724,500.00. Following the transaction, the insider now directly owns 2,646,972 shares of the company’s stock, valued at $91,294,064.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Phillip Md Et Al Frost acquired 280,183 shares of the stock in a transaction dated Friday, November 8th. The shares were purchased at an average cost of $1.50 per share, with a total value of $420,274.50. Following the transaction, the chief executive officer now directly owns 211,512,405 shares in the company, valued at approximately $317,268,607.50. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Opko Health, Inc. sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $34.49, for a total value of $1,724,500.00. Following the completion of the transaction, the insider now directly owns 2,646,972 shares in the company, valued at approximately $91,294,064.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 47.26% of the stock is owned by corporate insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.